Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
REVIEW
Naoki Hosen
One should identify appropriate cell surface targets to develop new CAR-T cells. Currently, lineage-specific antigens such as CD19 or B cell maturation antigen (BCMA) are being used as targets for CAR-T cells. However, in most cancers, lineage-specific antigens cannot be used as targets because targeting normal counterparts expressing them causes fatal toxicity. Cancer-specific transcripts have been extensively searched for using transcriptome analysis, but only a few candidates were reported. We have been working on identifying tumor-specific antigen structures, for example constitutively activated conformer of integrin b7 in multiple myeloma...
March 29, 2024: Inflammation and Regeneration
#22
JOURNAL ARTICLE
Leon Cords, Christoph Schaefers, Abdulaziz Kamili, Christian Hoffmann, Sophia Cichutek, Friedrich Haag, Susanne Polywka, Carsten Bokemeyer, Lisa Leypoldt, Winfried Alsdorf, Julian Schulze Zur Wiesch, Katja C Weisel
Not available.
March 28, 2024: Haematologica
#23
JOURNAL ARTICLE
Y C Jia, X X Wang, W T Qiang, J Liu, P Guo, J Lu, X Q Fan, H Y He, J Du
No abstract text is available yet for this article.
December 14, 2023: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
#24
Xin Wang, Ailin Zhao, Jinbing Zhu, Ting Niu
OBJECTIVE: Bispecific antibody (BsAbs) therapy represents a promising immunotherapeutic approach with manageable toxicity and noteworthy preliminary efficacy in treating patients with relapsed or refractory multiple myeloma (RRMM). The objective of this systematic review and meta-analysis was to compare the efficacy and safety of B-cell maturation antigen (BCMA)-targeted BsAbs and non-BCMA-targeted BsAbs in the treatment of RRMM patients. METHODS: PubMed/MEDLINE, Web of Science, EMBASE, Cochrane Library and meeting libraries were searched from inception to August 16th, 2023...
2024: Frontiers in Immunology
#25
JOURNAL ARTICLE
Aina Oliver-Caldés, Marta Español-Rego, Aintzane Zabaleta, Veronica Gonzalez-Calle, Sergio Navarro-Velázquez, Susana Inoges, Ascensión López-Díaz de Cerio, Valentin Cabañas, Nieves López-Muñoz, Paula Rodriguez-Otero, Juan Luis Reguera-Ortega, David F Moreno, Núria Martínez-Cibrian, Lucía López-Corral, Lorena Pérez-Amill, Beatriz Martin-Antonio, Laura Rosinol, Joan Cid, Natalia Tovar, Joaquin Saez-Peñataro, Miriam Lopez-Parra, Eulalia Olesti, Elena Guillen, Sara Varea, Luis Gerardo Rodríguez-Lobato, Anthony M Battram, Marta-Sonia Gonzalez-Perez, Andres Sanchez-Salinas, Azucena González-Navarro, Valentin Ortiz-Maldonado, Julio Delgado, Felipe Prosper, Manel Juan, Joaquin Martinez-Lopez, Jose M Moraleda, Maria Victoria Mateos, Alvaro Urbano-Ispizua, Bruno Paiva, Mariona Pascal, Carlos Fernández de Larrea
BACKGROUND: BCMA-CARTs improve results obtained with conventional therapy in the treatment of relapsed/refractory multiple myeloma. However, the high demand and expensive costs associated with CART therapy might prove unsustainable for health systems. Academic CARTs could potentially overcome these issues. Moreover, response biomarkers and resistance mechanisms need to be identified and addressed to improve efficacy and patient selection. Here, we present clinical and ancillary results of the 60 patients treated with the academic BCMA-CART, ARI0002h, in the CARTBCMA-HCB-01 trial...
March 11, 2024: Clinical Cancer Research
#26
Corynn Kasap, Adila Izgutdina, Bonell Patiño-Escobar, Amrik Kang, Nikhil Chilakapati, Naomi Akagi, Haley Johnson, Tasfia Rashid, Juwita Werner, Abhilash Barpanda, Huimin Geng, Yu-Hsiu T Lin, Sham Rampersaud, Daniel Gil-Alós, Amin Sobh, Daphné Dupéré-Richer, Gianina Wicaksono, K M Kawehi Kelii, Radhika Dalal, Emilio Ramos, Anjanaa Vijayanarayanan, Fernando Salangsang, Paul Phojanakong, Juan Antonio Camara Serrano, Ons Zakraoui, Isa Tariq, Veronica Steri, Mala Shanmugam, Lawrence H Boise, Tanja Kortemme, Elliot Stieglitz, Jonathan D Licht, William J Karlon, Benjamin G Barwick, Arun P Wiita
Despite the success of BCMA-targeting CAR-Ts in multiple myeloma, patients with high-risk cytogenetic features still relapse most quickly and are in urgent need of additional therapeutic options. Here, we identify CD70, widely recognized as a favorable immunotherapy target in other cancers, as a specifically upregulated cell surface antigen in high risk myeloma tumors. We use a structure-guided design to define a CD27-based anti-CD70 CAR-T design that outperforms all tested scFv-based CARs, leading to >80-fold improved CAR-T expansion in vivo...
February 28, 2024: bioRxiv
#27
REVIEW
Pooneh Soltantabar, Sheena Sharma, Diane Wang, Hoi-Kei Lon, Akos Czibere, Anne Hickmann, Mohamed Elmeliegy
B-cell maturation antigen (BCMA)-targeting immunotherapies (e.g., chimeric antigen receptor T cells (CAR-T) and bispecific antibodies (BsAbs)) have achieved remarkable clinical responses in patients with relapsed and/or refractory multiple myeloma (RRMM). Their use is accompanied by exaggerated immune responses related to T-cell activation and cytokine elevations leading to cytokine release syndrome (CRS) in some patients, which can be potentially life-threatening. However, systematic evaluation of the risk of CRS with BCMA-targeting BsAb and CAR-T therapies, and comparisons across different routes of BsAb administration (intravenous (i...
March 8, 2024: Clinical Pharmacology and Therapeutics
#28
JOURNAL ARTICLE
Leo Caillot, Emmanuel Sleiman, Ingrid Lafon, Marie-Lorraine Chretien, Pauline Gueneau, Alexandre Payssot, Romain Pedri, Daniela Lakomy, François Bailly, Julien Guy, Jean-Pierre Quenot, Hervé Avet-Loiseau, Denis Caillot
BACKGROUND: The outcome of patients with relapsed and refractory multiple myeloma (RRMM) previously treated with the three main classes of myeloma therapy [immunomodulatory drugs, proteasome inhibitors, and anti-CD38 antibodies] remains poor. Recently, based on the phase II pivotal KarMMa trial [showing prolonged overall survival (OS) and progression-free survival (PFS) among heavily treated patients], idecabtagene vicleucel (ide-cel), a B-cell maturation antigen (BCMA)- directed chimeric antigen receptor (CAR) T cell therapy has been approved in US for the treatment of RRMM...
March 6, 2024: Transplantation and cellular therapy
#29
EDITORIAL
Antonio Sacco, Aldo M Roccaro
No abstract text is available yet for this article.
March 7, 2024: Blood
#30
MULTICENTER STUDY
Meera Mohan, Jorge Monge, Nishi Shah, Danny Luan, Mark Forsberg, Vineel Bhatlapenumarthi, Metodi Balev, Anannya Patwari, Heloise Cheruvalath, Divaya Bhutani, Sharmilan Thanendrarajan, Binod Dhakal, Maurizio Zangari, Samer Al-Hadidi, Dennis Cooper, Suzanne Lentzsch, Frits van Rhee, Anita D'Souza, Aniko Szabo, Carolina Schinke, Rajshekhar Chakraborty
The objective of our study was to report real-world data on the safety and efficacy of standard-of-care teclistamab in patients with relapsed/refractory multiple myeloma (MM). This is a multi-institutional retrospective cohort study and included all consecutive patients that received at least one dose of teclistamab up until August 2023. One hundred and ten patients were included, of whom, 86% had triple-class refractory disease, 76% penta-refractory disease, and 35% had prior exposure to B-cell maturation antigen (BCMA)-targeting therapies...
March 5, 2024: Blood Cancer Journal
#31
JOURNAL ARTICLE
Jie Zhao, Hui Yang, Junnan Ge, Linyu Li, Qiong Yao, Shaolong He, Qiujuan Zhu, Ruiui Ren, Chunrui Li, Liangming Ma, Weiwei Tian, Jia Wei
Relapsed and refractory multiple myeloma (RRMM) and B-cell leukemia/lymphoma with extramedullary disease (EMD) have poor prognosis and high mortality, lack of effective therapeutic approaches. We reported for the first time that 6 patients with malignant hematological diseases with EMD received chimeric antigen receptor (CAR)-T treatment combined with pomalidomide, and CAR-T cells were treated with pomalidomide in vitro to determine its killing activity and cytokine secretion. Three patients with RRMM were given B cell maturation antigen (BCMA)-CAR-T therapy...
April 2024: Blood Sci
#32
JOURNAL ARTICLE
Aurélie Jourdes, Elise Cellerin, Cyrille Touzeau, Stéphanie Harel, Blandine Denis, Guillaume Escure, Emmanuel Faure, Simon Jamard, Francois Danion, Cécile Sonntag, Florence Ader, Lionel Karlin, Sarah Soueges, Clarisse Cazelles, Clémentine de La Porte des Vaux, Laurent Frenzel, Fanny Lanternier, Xavier Brousse, Titouan Cazaubiel, Pierre Berger, Aude Collignon, Mathieu Blot, Andrea Pieragostini, Morgane Charles, Carine Chaleteix, Alexis Redor, Virginie Roland, Tom Cartau, Margaret Macro, Thomas Chalopin, Nicolas Vallet, Aurore Perrot, Guillaume Martin-Blondel
OBJECTIVES: Bispecific antibodies (BsAbs) are an effective treatment used in relapsed/refractory multiple myeloma. Despite a well-tolerated safety profile, infectious events appeared to be frequent in clinical trials. Real-world data on epidemiology, characteristics, risk factors and outcomes of infections in patients treated with BsAb are still needed. METHODS: A retrospective, multicenter study in BsAb-treated MM patients was conducted in 14 French centers from December 2020 to February 2023...
March 1, 2024: Clinical Microbiology and Infection
#33
JOURNAL ARTICLE
Kevin Robert Reyes, Yen-Chun Liu, Chiung-Yu Huang, Rahul Banerjee, Thomas Martin, Sandy W Wong, Jeffrey Lee Wolf, Shagun Arora, Nina Shah, Ajai Chari, Alfred Chung
For patients with relapsed/refractory multiple myeloma (RRMM) with relapse following B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell therapies (CAR-T), optimal salvage treatment strategies remain unclear. BCMA-directed CAR-T and bispecific antibodies (BsAb) are now commercially available, and the outcomes for retreatment with BCMA-directed approaches are not well-studied. We performed a retrospective analysis of 68 patients with relapsed disease after BCMA-directed CAR-T to evaluate outcomes and responses to salvage therapies...
March 1, 2024: Blood Advances
#34
(no author information available yet)
No abstract text is available yet for this article.
March 1, 2024: Blood cancer discovery
#35
JOURNAL ARTICLE
Alana L Keller, Lauren T Reiman, Olivia Perez de Acha, Sarah E Parzych, Peter A Forsberg, Peter S Kim, Kamlesh Bisht, Hongfang Wang, Helgi Van de Velde, Daniel W Sherbenou
T cell engaging antibodies (TCEs) are showing promising efficacy in relapsed/refractory multiple myeloma (MM), even in patients that relapsed after BCMA targeted therapy. MM patients may have compromised T cell health unaccounted for by preclinical models. Here, we use Myeloma Drug Sensitivity Testing (My-DST) for ex vivo measurement of anti-MM cytotoxicity for the trispecific CD38/CD28xCD3 TCE SAR442257 through activation of the patients' own endogenous T cells to inform clinical development of the compound in MM...
February 29, 2024: Cancer Res Commun
#36
JOURNAL ARTICLE
Mohamad Mohty, Nizar J Bahlis, Ajay K Nooka, Marco DiBonaventura, Jinma Ren, Umberto Conte
The physical and emotional burden of relapsed or refractory multiple myeloma (RRMM) has been strongly correlated with declining health-related quality of life (QOL) in the patients it affects. This analysis evaluated patient-reported outcomes (PROs) from B-cell maturation antigen (BCMA)-naive (n = 123) and -exposed (n = 64) patients with RRMM enrolled in the MagnetisMM-3 study (NCT04649359) and treated with the humanized, bispecific BCMA-CD3 antibody elranatamab. Patients received two step-up doses of elranatamab (12 mg on day 1, 32 mg on day 4) before starting the full dose of 76 mg on day 8 (each cycle = 28 days)...
February 29, 2024: British Journal of Haematology
#37
JOURNAL ARTICLE
Won-Ho Lee, Charlotte E Graham, Hadley R Wiggin, Hannah K Nolan, Kiana J Graham, Felix Korell, Mark B Leick, Alexis L Barselau, Estelle Emmanuel-Alejandro, Michael A Trailor, Juliane M Gildea, Frederic Preffer, Matthew J Frigault, Marcela V Maus, Kathleen M E Gallagher
Chimeric antigen receptor (CAR) modified T cell therapies targeting BCMA have displayed impressive activity in the treatment of multiple myeloma. There are currently two FDA licensed products, ciltacabtagene autoleucel and idecabtagene vicleucel, for treating relapsed and refractory disease. Although correlative analyses performed by product manufacturers have been reported in clinical trials, there are limited options for reliable BCMA CAR T detection assays for physicians and researchers looking to explore it as a biomarker for clinical outcome...
February 28, 2024: Cytometry. Part B, Clinical Cytometry
#38
JOURNAL ARTICLE
Luciano J Costa, Thomas W LeBlanc, Hans Tesch, Pieter Sonneveld, Ryan P Kyle, Liliya Sinyavskaya, Patrick Hlavacek, Aster Meche, Jinma Ren, Alex Schepart, Didem Aydin, Guido Nador, Marco daCosta DiBonaventura
Elranatamab efficacy in the single-arm, registrational MagnetisMM-3 trial (NCT04649359) was compared with that of physician's choice of treatment (PCT) for triple-class refractory multiple myeloma. MagnestisMM-3 eligibility criteria were applied to two USA-based oncology electronic health record databases, COTA and Flatiron Health (FH), to identify cohorts for this study (NCT05932290). Applied statistical techniques accounted for cohort imbalances. MagnetisMM-3 (BCMA-naive; n = 123) outcomes were compared with those from COTA (n = 239) and FH (n = 152)...
February 28, 2024: Future Oncology
#39
REVIEW
Susan J Keam
Nirogacestat (OGSIVEO™) is an oral, selective, reversible, small molecule γ-secretase inhibitor developed by SpringWorks Therapeutics, Inc. γ-Secretase is a multi-subunit protease complex that cleaves multiple transmembrane protein complexes, including Notch and membrane-bound B-cell maturation antigen (BCMA). Inhibition of γ-secretase may result in growth inhibition of tumour cells overexpressing Notch, and preservation of membrane-bound BCMA may increase target density for BCMA-targeted therapy...
February 27, 2024: Drugs
#40
JOURNAL ARTICLE
Dai-Shi Tian, Chuan Qin, Ming-Hao Dong, Michael Heming, Luo-Qi Zhou, Wen Wang, Song-Bai Cai, Yun-Fan You, Ke Shang, Jun Xiao, Di Wang, Chun-Rui Li, Min Zhang, Bi-Tao Bu, Gerd Meyer Zu Hörste, Wei Wang
B-cell maturation antigen (BCMA), expressed in plasmablasts and plasma cells, could serve as a promising therapeutic target for autoimmune diseases. We reported here chimeric antigen receptor (CAR) T cells targeting BCMA in two patients with highly relapsed and refractory myasthenia gravis (one with AChR-IgG, and one with MuSk-IgG). Both patients exhibited favorable safety profiles and persistent clinical improvements over 18 months. Reconstitution of B-cell lineages with sustained reduced pathogenic autoantibodies might underlie the therapeutic efficacy...
February 26, 2024: EMBO Molecular Medicine
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
